Safety of Sofosbuvir and Ribavirin Combination Therapy in a Patient Who Developed Anemia due to Ribavirin

Interferon (IFN) and ribavirin (RBV) combination therapy was previously the standard of care for treatment of hepatitis C virus (HCV) genotype 2 infection. But, it often induced hemolytic anemia. In 2014, sofosbuvir (SOF) was approved for the treatment of chronic HCV genotype 2 in Japan. SOF/RBV the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Case Reports Hepatol
Autors principals: Suii, Hirokazu, Ozeki, Itaru, Tatsumi, Ryoji, Yamaguchi, Masakatsu, Kimura, Mutsuumi, Arakawa, Tomohiro, Nakajima, Tomoaki, Kuwata, Yasuaki, Ohmura, Takumi, Hige, Shuhei, Karino, Yoshiyasu, Toyota, Joji
Format: Artigo
Idioma:Inglês
Publicat: Hindawi 2017
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5742439/
https://ncbi.nlm.nih.gov/pubmed/29375917
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2017/8793895
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars